First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment-Reference-Cited by-同舟云学术

First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment

Published:2012-01-06 Issue:S1 Volume:15 Page:57-60
ISSN:1386-341X
Container-title:Pituitary
language:en
Short-container-title:Pituitary

Author:

Baldari S.,Ferraù F.,Alafaci C.,Herberg A.,Granata F.,Militano V.,Salpietro F. M.,Trimarchi F.,Cannavò S.

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s11102-011-0373-5.pdf

Reference30 articles.

1. Colao A, Di Sarno A, Pivonello R, Di Somma C, Lombardi G (2002) Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 11:787–800

2. Colao A (2009) Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 23:575–596

3. Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485–534

4. Acosta-Gómez MJ, Muros MA, Llamas-Elvira JM, Ramírez A, Ortega S, Sabatel G, Ramos C, de la Riva-Aguilar A (2005) The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours. Br J Radiol 78(926):110–115

5. Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H, Culler MD, Moreau JP, Enjalbert A (1999) Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 84(9):3268–3276

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prolactin Secreting Pituitary Carcinoma and the Role of Peptide Receptor Radionuclide Therapy: A Brief Report;Neurology India;2024-07

2. Treatment of an Aggressive Gonadotroph Pituitary Neuroendocrine Tumor With 177Lutetium DOTATATE Radionuclide Therapy;JCEM Case Reports;2024-06-27

3. Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment;Frontiers in Endocrinology;2024-02-02

4. Aggressive and Metastatic Pituitary Neuroendocrine Tumors: Therapeutic Management and Off-Label Drug Use;Journal of Clinical Medicine;2023-12-25

5. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment;Archives of Medical Research;2023-12